GlassScriptPhysician profile
Armando Gutierrez
NPI 1346839743
$4,310.72
in general payments reported to CMS, 2019-2025
18 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $1,509 · 2023: $1,413 · 2024: $721 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,653.61 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $452.88 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $392.68 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $382.97 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $252.02 | 2022-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $192.93 | 2021-2025 | Trintellix |
| Corium, LLC | $139.31 | 2023-2024 | Azstarys |
| Lundbeck LLC | $100.36 | 2021-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $71.78 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $64.57 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $26.66 | 2024-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $23.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.07 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $18.87 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.38 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.14 | 2024 | Quviviq |
| Eisai INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.